Artiva Biotherapeutics, Inc. RTVA
We take great care to ensure that the data presented and summarized in this overview for Artiva Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RTVA
Top Purchases
Top Sells
About RTVA
Insider Transactions at RTVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Jennifer Bush COO, CLO, Secy, Compliance Off |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+40.72%
|
-
|
|
Sep 12
2024
|
Neha Krishnamohan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Sep 12
2024
|
Christopher Horan Chief Tech Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Sep 12
2024
|
Thorsten Graef Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Sep 12
2024
|
Heather Raymon SVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
8,333,333
+46.11%
|
$99,999,996
$12.0 P/Share
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
461,687
+36.78%
|
$4,616,870
$10.2 P/Share
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,058,282
+50.0%
|
-
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Open market or private purchase
|
Indirect |
833,333
+41.35%
|
$9,999,996
$12.0 P/Share
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Other acquisition or disposition
|
Indirect |
461,687
+29.4%
|
$4,616,870
$10.2 P/Share
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Conversion of derivative security
|
Indirect |
1,058,284
+50.0%
|
-
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Open market or private purchase
|
Indirect |
416,666
+24.84%
|
$4,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Other acquisition or disposition
|
Indirect |
256,316
+23.3%
|
$2,563,160
$10.2 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Conversion of derivative security
|
Indirect |
354,972
+22.68%
|
-
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Open market or private purchase
|
Direct |
1,666,666
+33.51%
|
$19,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Other acquisition or disposition
|
Direct |
294,117
+15.2%
|
$2,941,170
$10.2 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Conversion of derivative security
|
Direct |
997,280
+29.67%
|
-
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Open market or private purchase
|
Direct |
416,666
+17.71%
|
$4,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Other acquisition or disposition
|
Direct |
461,687
+23.3%
|
-
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Conversion of derivative security
|
Direct |
1,058,284
+33.43%
|
-
|
Last 12 Months Summary
Buy / Acquisition
22.7M
Shares
From
23
Insiders
| Conversion of derivative security | 6.02M shares |
|---|---|
| Other acquisition or disposition | 2.53M shares |
| Open market or private purchase | 13.7M shares |
| Grant, award, or other acquisition | 384K shares |
Sell / Disposition
0
Shares
From
0
Insiders